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OBJECTIVES: To compare the cost-effectiveness of various cervical cancer (CxCa) 
screening algorithms to primary screening with the cobas HPV Test, which 
identifies HPV genotypes 16/18 individually while simultaneously detecting the 
other high-risk HPV types. METHODS: A cohort Markov model was developed to 
compare four CxCa screening strategies: (S1) cytology with reflex HPV, (S2) 
cytology and HPV co-testing, (S3) HPV with reflex cytology, and (S4) cobas HPV 
with genotyping and reflex cytology. Screening began at age 30 with a routine 
screening interval of every 3 years, and was modeled over a time horizon of 40 
years. Performance of the overall screening strategies, ie, sensitivity and 
specificity for CIN 2/3, was derived from the ATHENA (Addressing THE Need for 
Advanced HPV Diagnostics) trial. Trial baseline data were used for the base case, 
and 1-year follow-up outcomes were estimated for the alternative scenario, 
assuming all persistent disease is detected in the subsequent visit. The direct 
costs for screening and treatment of CxCa were estimated from a US payer 
perspective in 2010 US dollars. Costs and quality-adjusted life years (QALYs) 
were discounted at 3% annually. One-way sensitivity analyses were conducted. 
RESULTS: Using a $50,000/QALY threshold, baseline screening with S4 
dominated S2 and S3 by reducing overall cost, annual cancer incidence, and 
improving QALYs; and was cost-effective compared to S1. In the 1-year follow-up 
scenario, S4 was cost-effective compared to all other strategies. Detection of HPV 
16/18 with S4 resulted in earlier diagnosis of clinically relevant CIN 2/3 at the 
initial visit as well as more efficient use of screening tests during follow-up. 
Sensitivity analyses showed that the model results were most influenced by the 
costs of tests used. CONCLUSIONS: Incorporating the cobas HPV test with HPV 
16/18 genotyping was cost-effective compared to various CxCa screening 
strategies, and resulted in improved protection against CxCa.  
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OBJECTIVES: To compare the costs and outcomes of enzalutamide versus 
abiraterone for the treatment of docetaxel refractory metastatic castrate 
resistant prostate cancer (mCRPC) from a limited societal perspective using a 
lifetime horizon. METHODS: We developed a Markov model with 3 health states: 
pre-progression, post-progression, and death with 1 month transitions. 
Transition probabilities for all health states were derived from the pivotal phase 
3 clinical trials: AFFIRM (enzalutamide) and COU-AA-301 (abiraterone). A 3% 
discount was applied to all costs and outcomes. Costs included drug acquisition 
costs, laboratory tests associated with treatment, as well as costs for grade 3/4 
side effects management. Outcomes were assessed in quality-adjusted life-years 
(QALYs). We conducted 16 univariate sensitivity analyses varying model inputs 
(overall survival, progression-free survival, utility, drug acquisition cost) for each 
respective drug independently by 20%. RESULTS: In the base case analysis, we 
found that the costs for enzalutamide were higher than that of abiraterone, 
primarily due to higher acquisition costs ($84465, $74119 respectively). 
Enzalutamide was also associated with greater life years gained than abiraterone 
(1.39, 1.30 respectively) as well as QALYs gained (1.24, 1.05 respectively). The ICER 
was $55070/QALY. Sensitivity analyses indicated that the ICER varied widely; 
using commonly accepted thresholds of $50000/QALY and $100000/QALY, we 
found that out of the 16 sensitivity analyses conducted, 4 fell below the 
$50000/QALY threshold and 7 fell below the $100000/QALY threshold. 
CONCLUSIONS: The treatment landscape of mCRPC has shifted dramatically in 
recent years. Where there previously had been few options for patients, the last 
2 years have brought multiple new therapies for mCRPC. To our knowledge, this 
is the first study which compares the cost-effectiveness of enzalutamide to 
abiraterone. Our results suggest that there is considerable uncertainty regarding 
the cost-effectiveness of enzalutamide, but enzalutamide will likely play a 
significant role in the treatment of mCRPC.  
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OBJECTIVES: In South Africa, females with over expressed human epidermal 
growth factor receptor 2 (HER2) positive metastatic breast cancer are often 
treated with trastuzumab. Lapatinib is an oral dual tyrosine kinase inhibitor and 
is indicated, in combination with capecitabine, for the treatment of patients with 
advanced or metastatic breast cancer. We estimate the cost-effectiveness of the 
use of lapatinib in the private health care sector from a payer perspective. 
METHODS: A cost-utility model was modified for appropriate application in the 
South African private health care sector setting. We compared treatment with 
capcitabine mono-therapy with several trastuzumab combination therapies as 
well as lapatinib in combination with capcitabine. Efficacy data was taken from 
the EGF100151 trial. The efficacy of trastuzumab containing regiment was 
assumed to be the same as that of a lapatanib containing regiment due to a lack 
of data. Sixteen key opinion leader oncologists were consulted through a 
structured questionnaire. Resource consumption costs were estimated from 
large private medical scheme claims data. A multistate model was used and run 
for the full lifetime of a patient. RESULTS: Lapatinib in combination with 
capecitabine dominates the combination of other treatment options investigated 
in this study. The incremental cost in this comparison equates to -US$3,619 with 
a gain of 0.032 quality adjusted life-years. The results were robust under 
sensitivity analyses. CONCLUSIONS: The use of lapatinib dominates other 
treatments. The majority (84%) of patients in the comparator arm use 
trastuzumab, and based on the fact that the AE costs are relatively low, the 
results are mainly driven by the difference in the cost of trastuzumab and 
lapatinib. The validity of the assumption of equal efficacy of trastuzumab and 
lapatinib is therefore key when interpreting the results and needs to be verified 
with additional data.  
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OBJECTIVES: To explore the chronic myeloid leukemia (CML)-related health  
care costs, utilizations associated with nonadherence and interruption of 
tyrosine kinase inhibitors (TKIs) in newly diagnosed CML patients. METHODS: 
This retrospective cohort study was conducted from 2003 to 2011 using the 
Taiwan Health Insurance Research Database. Newly diagnosed CML patients 
who received TKIs (imatinib, dasatinib and nilotinib) for more than one year 
during 2003 to 2010 were included in this study, and followed from the first TKI 
prescription date to death or end of study. CML-related medical utilization 
(number of outpatient and inpatient visits) and costs were calculated  
and stratified by TKI utilization pattern comparing interruption versus 
persistence and non-adherence versus adherence. Any gap between  
two consecutive prescriptions for more than 60 days and medicine possess ratio 
less than 80% were defined as interruption and non-adherence. Data were 
analyzed by generalized linear models with log link and gamma distributions. 
RESULTS: Of the 991 included patients, 24.6% and 15.8% were identified  
as interruption and non-adherence groups. Non-adherence and interruption 
rates were higher in patients who received increasing dose of imatinib, imatinib 
switched to dasatinib and imatinib switched to nilotinib. Adjusted outpatient 
cost per person year was higher in persistence (US$31,443±1,456)  
than interruption (US$22,071±1,163) group (p<0.0001); and higher in adherence 
(US$30,295±1,230) than non-adherence (US$18,259±1,050) group (p<0.0001). 
However, adjusted inpatient cost per person year was higher in interruption 
(US$5,674±1,665 vs. US$2,442±613; p<0.0001) and non-adhernece (US$6,390±1,866 
vs. US$2,260±557; p<0.0001) groups. Likewise, CML-related inpatient visits  
per person year was higher in interruption (1.3 vs. 0.9; p=0.0093) and non-
adherence (1.4 vs. 0.9; p=0.0251). CONCLUSIONS: Interruption and non-
adherence to TKIs are associated with higher inpatient utilization and costs. 
Further study need to evaluate the clinical consequence and costs related to TKIs 
interruption and nonadherence for maximizing the efficiency of medical 
utilizations.  
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OBJECTIVES: Even though prostate cancer has one of the highest incidences of 
cancer, there is very limited data available on treatment patterns in Brazil. This 
study aimed to describe treatment patterns and health care resource utilization 
associated with PC in Brazil in 2012. METHODS: Overall clinical practice for 
management of prostate cancer was investigated through a physician face-to-
face survey. Eligible criteria were medical oncologists and/or urologists with 
clinical experience with prostate cancer patients, including hormonal therapy, 
with a minimum volume of 30 patients/month. Clinical experts were 
consecutively selected based on a high prescriber database and stratified by type 
of health care sector (public/private). RESULTS: Twenty physicians (70% 
oncologists; 30% urologists) currently treating 1,325 patients answered the 
questionnaire. Significant differences were found on treatment patterns when 
comparing public and private health care physician responses. In localized PC 
patients, radical prostatectomy was more commonly used in the private than in 
the public settings. For advanced stage patients, surgical androgen deprivation 
therapy (ADT) was used in 7% in private health care and in 37% of public 
patients. In metastatic castration resistant patients (mCRPC), first line 
chemotherapy of choice was docetaxel. However, second line treatment varied 
between mitoxantrone (32% private, 50% public), cabazitaxel (54% private, 18% 
public) and docetaxel re-challenge (11% private, 29% public). Health care resource 
utilization increases as disease progresses: from mean 14.1 blood tests/year 
(blood count, blood chemistry, functional liver test and PSA) in localized PC while 
receiving treatment to 22 blood tests/year in advanced tumor and 40.05 blood 
tests/year in mCRPC. The same trend is observed with specialist visits and 
emergency room, but not with image testing. CONCLUSIONS: Both treatment 
patterns and resource use are different when comparing private and public 
settings. Access to new technologies may be an important factor in explaining 
this difference.  
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